109 related articles for article (PubMed ID: 34906120)
1. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
Klingbiel D; Saridaki Z; Roth AD; Bosman FT; Delorenzi M; Tejpar S
Ann Oncol; 2015 Jan; 26(1):126-132. PubMed ID: 25361982
[TBL] [Abstract][Full Text] [Related]
3. Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study.
van den Berg I; van de Weerd S; Roodhart JML; Vink GR; van den Braak RRJC; Jimenez CR; Elias SG; van Vliet D; Koelink M; Hong E; van Grevenstein WMU; van Oijen MGH; Beets-Tan RGH; van Krieken JHJM; IJzermans JNM; Medema JP; Koopman M;
BMC Cancer; 2020 Aug; 20(1):776. PubMed ID: 32811457
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.
Lau D; Kalaitzaki E; Church DN; Pandha H; Tomlinson I; Annels N; Gerlinger M; Sclafani F; Smith G; Begum R; Crux R; Gillbanks A; Wordsworth S; Chau I; Starling N; Cunningham D; Dhillon T
ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079623
[TBL] [Abstract][Full Text] [Related]
5. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
[TBL] [Abstract][Full Text] [Related]
6. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
[TBL] [Abstract][Full Text] [Related]
7. Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial).
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsui S; Teramukai S; Murotani K; Ajioka Y; Shimazaki H; Maeda A; Takuma K; Yoshida T; Kambara T; Matsuda K; Takagane A; Tomita N; Sugihara K;
Am J Surg Pathol; 2020 Dec; 44(12):1685-1698. PubMed ID: 32868525
[TBL] [Abstract][Full Text] [Related]
8. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
Pietrantonio F; Miceli R; Raimondi A; Kim YW; Kang WK; Langley RE; Choi YY; Kim KM; Nankivell MG; Morano F; Wotherspoon A; Valeri N; Kook MC; An JY; Grabsch HI; Fucà G; Noh SH; Sohn TS; Kim S; Di Bartolomeo M; Cunningham D; Lee J; Cheong JH; Smyth EC
J Clin Oncol; 2019 Dec; 37(35):3392-3400. PubMed ID: 31513484
[TBL] [Abstract][Full Text] [Related]
9. Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study.
Pu H; Yang W; Liu M; Pang X; Chen Y; Xiong Q
Sci Rep; 2024 Mar; 14(1):6889. PubMed ID: 38519578
[TBL] [Abstract][Full Text] [Related]
10. A new prognostic and predictive tool for shared decision making in stage III colon cancer.
Sobrero AF; Puccini A; Shi Q; Grothey A; Andrè T; Shields AF; Souglakos I; Yoshino T; Iveson T; Ceppi M; Bruzzi P
Eur J Cancer; 2020 Oct; 138():182-188. PubMed ID: 32892120
[TBL] [Abstract][Full Text] [Related]
11. Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.
Ortiz-Ortiz KJ; Tortolero-Luna G; Ríos-Motta R; Veintidós-Feliú A; Hunter-Mellado R; Torres-Cintrón CR; Suárez-Ramos T; Magno P
PLoS One; 2018; 13(3):e0194415. PubMed ID: 29584752
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.
Jin Z; Dixon JG; Fiskum JM; Parekh HD; Sinicrope FA; Yothers G; Allegra CJ; Wolmark N; Haller D; Schmoll HJ; de Gramont A; Kerr R; Taieb J; Van Cutsem E; Tweleves C; O'Connell M; Saltz LB; Sadahiro S; Blanke CD; Tomita N; Seitz JF; Erlichman C; Yoshino T; Yamanaka T; Marsoni S; Andre T; Mahipal A; Goldberg RM; George TJ; Shi Q
J Natl Cancer Inst; 2021 Nov; 113(12):1693-1704. PubMed ID: 34405233
[TBL] [Abstract][Full Text] [Related]
13. Effects of Adjuvant Chemotherapy on Early-onset Stage II Colon Cancer at Different Tumor Sites.
Tan C; Wang Q; Yao S
Am J Clin Oncol; 2024 Jun; 47(6):253-258. PubMed ID: 38251762
[TBL] [Abstract][Full Text] [Related]
14. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
Srivastava G; Renfro LA; Behrens RJ; Lopatin M; Chao C; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim G; Mazurczak M; Lee M; Alberts SR
Oncologist; 2014 May; 19(5):492-7. PubMed ID: 24710310
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors associated with relapse of stage II/III colon cancer treated with peroral anti-cancer agents in the adjuvant setting.
Mizuuchi Y; Tanabe Y; Sada M; Kitaura Y; Nagai S; Watanabe Y; Tamiya S; Nagayoshi K; Ohuchida K; Nakano T; Nakamura M
Mol Clin Oncol; 2021 Jun; 14(6):122. PubMed ID: 33936595
[TBL] [Abstract][Full Text] [Related]
16. SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS).
Saunders MP; Iype R; Kelly C; Crosby J; Kerr R; Harkin A; Allan K; McQueen J; Pearson SR; Cassidy J; Medley LC; Raouf S; Harrison M; Brewster A; Rees C; Ellis R; Thomas AL; Churn M; Iveson T; Maka N
Clin Colorectal Cancer; 2023 Jun; 22(2):231-237. PubMed ID: 36967267
[TBL] [Abstract][Full Text] [Related]
17. A recurrence-predictive model based on eight genes and tumor mutational burden/microsatellite instability status in Stage II/III colorectal cancer.
Gao Z; Wan Z; Yu P; Shang Y; Zhu G; Jiang H; Chen Y; Wang S; Lei F; Huang W; Zeng Q; Wang Y; Rong W; Hong Y; Gao Q; Niu P; Zhai Z; An K; Ding C; Wang Y; Gu G; Wang X; Meng Q; Ye S; Liu H; Gu J
Cancer Med; 2024 Jan; 13(1):e6720. PubMed ID: 38111983
[TBL] [Abstract][Full Text] [Related]
18. Trends and Prescriber Variation in the Duration of Oxaliplatin-Containing Adjuvant Chemotherapy for Stage III Colon Cancer From 2007 to 2019: A Population-Based Retrospective Cohort Study.
Sue-Chue-Lam C; Brezden-Masley C; Sutradhar R; Yu AYX; Baxter NN
Clin Colorectal Cancer; 2023 Dec; 22(4):431-441.e9. PubMed ID: 37648568
[TBL] [Abstract][Full Text] [Related]
19. What We Know About Stage II and III Colon Cancer: It's Still Not Enough.
Puccini A; Berger MD; Zhang W; Lenz HJ
Target Oncol; 2017 Jun; 12(3):265-275. PubMed ID: 28504299
[TBL] [Abstract][Full Text] [Related]
20. Complete Obstruction, a Real Risk Factor: A Comprehensive Study on Obstruction in Stage IIA Colon Cancer With Propensity Score Matching Analysis.
Oh SY; Kim CW; Kim S; Kim MH; Kim YI; Lee JL; Yoon YS; Park IJ; Lim SB; Yu CS
Clin Colorectal Cancer; 2024 Jun; 23(2):135-146.e3. PubMed ID: 38749791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
